NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
Final draft guidance recommends D‑VRd on the NHS in England and Wales
Read More
Author: John Pinching
Anocca doses first patients with precision TCR‑T therapy
Company begins phase 1 treatment in multi‑centre VIDAR‑1 trial
Read More
Connecta launches phase 2a trial of neuroplasticity modulator
Study marks major milestone for CTH120 as company advances disease‑modifying ambitions
Read More
Aquipta recommended by NICE for acute migraine treatment
Guidance paves the way for NHS access for eligible adults in England and Wales
Read More
Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
SMC backs first GPRC5D‑targeting bispecific for patients after three or more treatments
Read More- NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
- Anocca doses first patients with precision TCR‑T therapy
- Connecta launches phase 2a trial of neuroplasticity modulator
- Aquipta recommended by NICE for acute migraine treatment
- Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
